Safety of Ticagrelor in Post – PCI (Percutaneous Coronary Intervention) Patients at a Tertiary Care Hospital
Article Sidebar
Main Article Content
Abstract
Background: Coronary artery disease (CAD) remains a leading cause of mortality and morbidity worldwide, despite advances in diagnosis and management. In acute coronary syndrome (ACS) patients, the combination of aspirin and clopidogrel is the standard therapy against recurrent cardiovascular events. However, clopidogrel has a delayed onset and variability in platelet response.
Objective: To examine the safety profile of ticagrelor in post-PCI patients at a tertiary care hospital.
Methods: This descriptive study was conducted at the Department of Cardiology, North-West General Hospital, Peshawar, from 1st April 2023 to 31st March 2024. Patients aged 30 to 80 years who underwent PCI and were started on ticagrelor were included. Baseline data such as age, gender, BMI, and cardiovascular risk factors (smoking, hypertension, diabetes mellitus) were collected. Patients received a loading dose of ticagrelor 180 mg orally followed by 90 mg twice daily. Adverse effects, including bleeding, dyspnea, and arrhythmias, were evaluated within 24 hours and at one-month follow-up. Data were analyzed using IBM SPSS version 25, with categorical variables presented as frequencies and percentages, and quantitative variables as means and standard deviations.
Results: A total of 137 post-PCI patients participated in the study, with a mean age of 58 ± 10 years. The cohort included 85 men (62%) and 52 women (38%). The average BMI was 27.5 ± 3.5 kg/m². Risk factors included smoking (30%), hypertension (45%), and diabetes mellitus (25%). Within 24 hours, minor bleeding occurred in 10 patients (7.3%), dyspnea in 15 patients (10.9%), and arrhythmias in 4 patients (2.9%). At the one-month follow-up, minor bleeding was observed in 12 patients (8.8%), major bleeding in 2 patients (1.5%), dyspnea in 18 patients (13.1%), and arrhythmias in 5 patients (3.6%).
Conclusion: The study supports the safety of ticagrelor as an antiplatelet therapy in post-PCI patients, with manageable adverse effects. However, careful monitoring for complications such as bleeding, dyspnea, and arrhythmias is recommended.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, et al. Global, Regional, and National Burden of Cardiovascular Diseases for 10 Causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1-25.
Libby P, Theroux P. Pathophysiology of Coronary Artery Disease. Circulation. 2005;111(25):3481-3488.
Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233-241.
Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. J Am Coll Cardiol. 2004;44(3).
Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthelemy O, et al. Cardiovascular Risk in Clopidogrel-Treated Patients According to Cytochrome P450 2C19* 2 Loss-of-Function Allele or Proton Pump Inhibitor Coadministration: A Systematic Meta-Analysis. J Am Coll Cardiol. 2010;56(2):134-143.
Butler K, Teng R, Gurbel PA, Kereiakes DJ, Jakubowski JA, Storey RF. Pharmacokinetics, Pharmacodynamics, and Safety of Ticagrelor in Patients With Stable Coronary Artery Disease: A Meta-Analysis and Systematic Review. J Am Coll Cardiol. 2020;75(14):1620-1632.
Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, Pharmacokinetics, and Safety of the Oral Reversible P2Y12 Antagonist AZD6140 With Aspirin in Patients With Atherosclerosis: A Double-Blind Comparison to Clopidogrel With Aspirin. Eur Heart J. 2006;27(9):1038-1047.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, et al. Long-Term Use of Ticagrelor in Patients With Prior Myocardial Infarction. N Engl J Med. 2015;372(19):1791-1800.
James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, et al. Ticagrelor vs Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery: Results From the PLATO (PLATelet Inhibition and Patient Outcomes) Trial. J Am Coll Cardiol. 2010;56(22):1854-1862.
Li X, Yang YN, Ma YT, Liu F, Huang D. Safety and Efficacy of Ticagrelor Versus Clopidogrel in Chinese Patients With Acute Coronary Syndrome: A Systematic Review and Meta-Analysis. Chin Med J (Engl). 2018;131(4):485-492.
Steg PG, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, et al. ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation. Eur Heart J. 2012;33(20):2569-2619.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, et al; TRITON-TIMI 38 Investigators. Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndromes. N Engl J Med. 2007;357(20):2001-2015.
Pan Li X, Yang YN, Zhang CH, Ma YT, Liu F, Huang D. Safety and Efficacy of Ticagrelor in East Asian Patients With Acute Coronary Syndrome: A Meta-Analysis and Systematic Review. Chin Med J (Engl). 2022;135(5):610-618.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes. N Engl J Med. 2021;385(3):221-231.
Berger JS, Bhatt DL. Aspirin and Clopidogrel in Acute Coronary Syndrome and Other Indications. Cardiovasc Drugs Ther. 2009;23(5):393-400.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes. N Engl J Med. 2009;361(11):1045-1057.
Ueapornpanith P, Buranakiti B, Chotayaporn T, Phrommintikul A, Yoodee V. Safety outcomes of ticagrelor among patients with STE-ACS post streptokinase therapy-a retrospective observational study. Plos one. 2023 Aug 4;18(8):e0289721.
Mendieta G, Mehta S, Baber U, Angiolillo DJ, Briguori C, Cohen D, Collier T, Dangas G, Dudek D, Escaned J, Gil R. Bleeding and ischemic risks of ticagrelor monotherapy after coronary interventions. Journal of the American College of Cardiology. 2023 Aug 22;82(8):687-700.
Herron GC, Bates ER. Review of the Ticagrelor Trials Evidence Base. Journal of the American Heart Association. 2024 May 28:e031606.
Baber U, Jang Y, Oliva A, Cao D, Vogel B, Dangas G, Sartori S, Spirito A, Smith KF, Branca M, Collier T. Safety and efficacy of ticagrelor monotherapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: an individual patient data meta-analysis of TWILIGHT and TICO randomized trials. Circulation. 2024 Feb 20;149(8):574-84.